BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17805970)

  • 1. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease.
    Afzal NA; Ozzard A; Keady S; Thomson M; Murch S; Heuschkel R
    Dig Dis Sci; 2007 Dec; 52(12):3329-33. PubMed ID: 17805970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for ulcerative colitis in children and adolescents.
    McGinnis JK; Murray KF
    J Clin Gastroenterol; 2008 Sep; 42(8):875-9. PubMed ID: 18645529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
    Teshima CW; Thompson A; Dhanoa L; Dieleman LA; Fedorak RN
    Can J Gastroenterol; 2009 May; 23(5):348-52. PubMed ID: 19440565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
    Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
    J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
    Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A
    Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
    Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
    de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
    Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
    Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
    Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
    J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
    Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
    Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of infliximab in treatment of pediatric Crohn's disease in China].
    Luo Y; Yu J; Zhao H; Peng K; Lou J; Ma M; Chen J
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):688-92. PubMed ID: 25476432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.